Sulbactam S010-10MG

产品介绍

Sulbactam is an irreversible inhibitor of several bacterial penicillinases and cephalosporinases. In the presence of low concentrations of sulbactam, ampicillin and other β-lactams readily inhibit the growth of a variety of resistant bacteria that contain β-lactamases. Sulbactam was first developed by the central research division of Pfizer, Inc. and was first described in 1978.

Sulbactam used alone displays only weak antibacterial activity, with the notable exception of its potent effects on susceptible and resistant strains of Neisseria gonorrhoeae. Sulbactam sodium appears to be somewhat less potent but markedly more stable (in aqueous solution) than the β-lactamase inhibitor clavulanic acid.  

Sulbactam is able to inhibit the most common forms of β-lactamase but is not able to interact with the AmpC cephalosporinase. Thus, it confers little protection against bacteria such as Pseudomonas aeruginosa, Citrobacter, Enterobacter, and Serratia, which often express this gene.

Sulbactam is commonly combined with ampicillin to form Ampicillin/Sulbactam (2:1). It does possess some antibacterial activity when administered alone, but it is too weak to have any clinical importance. 

Recently, sulbactam has been used in treating Acinetobacter septicemia and is receiving renewed interest.

Synonyms: (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide, Betamaze, CP 45899, CP-45,899, Penicillanic acid 1,1-dioxide, Penicillanic acid S,S-dioxide, Penicillanic acid dioxide, Penicillanic acid sulfone